Inventiva S.A. focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH),mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH.
